This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Neovasc Future Growth

Future criteria checks 0/6

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth	16.2%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	10 Feb 2023

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

TSX:NVCN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	10	-23	N/A	N/A	1
12/31/2022	4	-41	-25	-25	N/A
9/30/2022	3	-34	-24	-24	N/A
6/30/2022	3	-33	-25	-25	N/A
3/31/2022	3	-33	-26	-25	N/A
12/31/2021	3	-25	-27	-27	N/A
9/30/2021	2	-23	-30	-29	N/A
6/30/2021	2	-26	-31	-31	N/A
3/31/2021	2	-27	-32	-31	N/A
12/31/2020	2	-29	-30	-29	N/A
9/30/2020	2	-37	-29	-29	N/A
6/30/2020	2	-33	-27	-27	N/A
3/31/2020	2	-31	-25	-25	N/A
12/31/2019	2	-35	-24	-24	N/A
9/30/2019	2	-11	-24	-24	N/A
6/30/2019	2	-20	-23	-23	N/A
3/31/2019	2	-61	-24	-24	N/A
12/31/2018	2	-108	-23	-23	N/A
9/30/2018	2	-125	-141	-141	N/A
6/30/2018	3	-115	-140	-140	N/A
3/31/2018	4	-71	-138	-138	N/A
12/31/2017	5	-22	-139	-139	N/A
9/30/2017	7	19	-22	-21	N/A
6/30/2017	9	-5	-29	-28	N/A
3/31/2017	9	-83	-36	-35	N/A
12/31/2016	10	-86	-40	-40	N/A
9/30/2016	9	-131	N/A	-39	N/A
6/30/2016	8	-110	N/A	-35	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if NVCN's forecast earnings growth is above the savings rate (1.8%).

Earnings vs Market: Insufficient data to determine if NVCN's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if NVCN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if NVCN's revenue is forecast to grow faster than the Canadian market.

High Growth Revenue: Insufficient data to determine if NVCN's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NVCN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

This company has been acquired

Neovasc Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

ShockWave Medical, Inc. (NasdaqGS:SWAV) entered into a definitive agreement to acquire Neovasc Inc. (TSX:NVCN) from Strul Medical Group LLC and others for $75.04 million.

Is Neovasc (TSE:NVCN) Using Too Much Debt?

Neovasc Announces Progress on COSIRA-II Clinical Trial

Insufficient new directors

Insufficient new directors

Neovasc Inc. to Report Q3, 2022 Results on Nov 10, 2022

Insufficient new directors

Independent Director recently bought CA$56k worth of stock

Neovasc Inc. Announces Positive Clinical Data at Transcatheter Cardiovascular Therapeutics Conference and Provides Update on Mitral Valve Program

Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina

Independent Director recently bought CA$99k worth of stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Neovasc Inc. to Report Q2, 2022 Results on Aug 11, 2022

Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations

Independent Director recently bought CA$50k worth of stock

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Neovasc Inc. to Report Q1, 2022 Results on May 12, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Neovasc Inc. to Report Q4, 2021 Results on Mar 10, 2022

Neovasc Inc., Annual General Meeting, Apr 12, 2022

German Institute for the Hospital Remuneration System Awards Neovasc, Inc.'s Reducer™ NUB Status 1 Designation for 2022

Neovasc Inc. Announces the Publication of Cost-Effectiveness Studies Supporting the Use of the Neovasc Reducer

Neovasc Inc. Announces Complete Dismissal of Securities Class Action Complaint with Prejudice

Neovasc Inc. Announces Case Series of First U.S. Reducer Implants Published in Peer-Reviewed Journal

Neovasc Announces First Patient Enrollment in Cosira-II Trial

Chief Operating Officer recently bought CA$101k worth of stock

The National Institute for Health and Care Excellence of the United Kingdom Provides Positive Guidance for Neovasc Reducer System

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.51 loss in 3Q 2020)

Independent Director recently bought CA$97k worth of stock

Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.81 loss in 2Q 2020)

Independent Director recently bought CA$108k worth of stock

Neovasc Inc Provides Corporate Update

Is Neovasc (TSE:NVCN) Using Debt Sensibly?

Neovasc Reducer System Receives First National Reimbursement in Europe

Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

Neovasc Inc. Provides Update on German Litigation

Neovasc Announces First Patient Enrollment in COSIMA Trial

First quarter 2021 earnings released: US$0.04 loss per share (vs US$0.38 loss in 1Q 2020)

Full year 2020 earnings released: US$1.72 loss per share (vs US$5.40 loss in FY 2019)

Revenue and earnings miss expectations

Independent Director recently bought CA$62k worth of stock

Neovasc Inc. to Report Q4, 2020 Results on Mar 11, 2021

What You Need To Know About Neovasc Inc.'s (TSE:NVCN) Investor Composition

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

American Medical Association Issues New CPT Code for Neovasc Reducer Procedure

New 90-day high: CA$1.72

Neovasc Inc. Responds to FDA Not-Approvable Letter Regarding Neovasc Reducer(TM)

Zhang Investor Law Alerts Investors to Upcoming Deadline in Securities Class Action Lawsuit Against Neovasc Inc

Pomerantz LLP Announces A Class Action Lawsuit Filed Against Neovasc Inc. and Certain of Its Officers

Neovasc Announces First Neovasc Reducer Implants in France

Neovasc Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Neovasc Inc. has completed a Follow-on Equity Offering in the amount of $6.10681 million.

Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

New 90-day low: CA$0.93

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Neovasc Inc

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Neovasc Inc. (NVCN) Investors

Pawar Law Group Announces A Securities Class Action Lawsuit Against Neovasc Inc

New 90-day low: CA$0.96

Third quarter 2020 earnings released: US$0.51 loss per share

Revenue beats expectations, earnings disappoint

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Neovasc Inc

New 90-day low: CA$2.66

Neovasc, Inc. Treats 300 Patient in Germany with the Neovasc Reducer

New 90-day low - CA$2.75

Neovasc Inc. has completed a Follow-on Equity Offering in the amount of $12.581842 million.

New 90-day low - CA$3.05

Earnings released

Neovasc Inc. to Report Q2, 2020 Results on Aug 06, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity